This month, on the occasion of the fifth anniversary of Xiling Lab Pharmaceutical Co., Ltd. (hereinafter referred to as "Xiling Lab"), the Company announced that it had successfully completed its Series A round of financing of RMB 90 million.

 

The financing was led by Shenzhen Share Zeshan Precision Medicine Investment Partnership (“Shenzhen Share Investment”), and followed by Changjiang Securities Innovation Investment (Hubei) Co., Ltd. and its follower (“Changjiang Securities Innovation Investment”), the fund under Shining Capital - Beijing Yizhuang Medicine Venture Capital Center for SMEs (Limited Partnership), and Chengdu Mingxi Biotechnology Co., Ltd. The funds obtained from this round of financing will mainly be used to accelerate the development of original new drugs, application and production of contrast agents.

 

 

Adhering to the principle of "value-driven, scientific decision-making, pragmatic innovation, willing to struggle", Xiling Lab is devoted to the development of global original new drugs and the construction of unique platforms with independent intellectual property rights. At present, it has over 10 original new drug development projects, involving gastrointestinal diseases, tumors, and ophthalmology.

 

Recently, Xiling Lab successfully signed a cooperation agreement on eribulin project with a European company. According to the successful development experience and technology for eribulin, the Company has carried out ADC product development based on eribulin and its derivatives and constructed XL-XDC technology platform with proprietary intellectual property rights. Meanwhile, Xiling Lab plans to complete the development of the second contrast agent API, produce the preparations by the system of permit-holders for the sale of pharmaceuticals to accelerate marketing of the drugs and benefit patients.

 

...

 

For this round of financing, Dr. Huang Jinkun, founder, chairman and CEO of Xiling Lab expressed that

 

“After this round of financing, Xiling Lab will combine its advantages in R&D of catalysis technique (XL-CATTECH) and TOXIN as well as linker design, and focus on the layout of XL-XDC technology platform with independent intellectual property rights to form the core competitive advantage of original new drugs. In addition, Xiling Lab hopes to rapid market more contrast agents through cooperation with external companies. We sincerely appreciate the trust and support by investors to Xiling Lab in this round of financing and we will continue to strive to achieve our company's commitment, that is, to let patients benefit and to win together with customers."

 

 

Mr. Huang Fanzhi, co-founder of Shenzhen Share Investment Co., Ltd. expressed that,

 

"We attach great importance to the R&D team and technical platform of Xiling Lab. We are looking forward to helping the Company bring the contrast agents and new drugs to the market as soon as possible so as to benefit more patients."

 

 

About Xiling Lab

 

 

Chengdu Xiling Lab is a new prominent drug R&D company based in China with its operations running globally. It has three wholly-owned subsidiaries, Chengdu Kelingyuan Pharmaceutical Technology Co., Ltd., Kelingyuan Biotechnology (Shenzhen) Co., Ltd. and Australia GUIXI PHARMATECH PTY LTD. Driven by innovation and cooperation, Xiling Lab company is committed to building an international leading innovative drug research and development platform, XL-XDC platform, contrast agent drug development platform and catalytic technology platform, so as to develop safe and effective clinical medication for patients in China and all over the world. Xiling Lab has the qualification of "National High-Tech Enterprise", and its core technology and management team have won the title of "Top Innovation and Entrepreneurship Team" awarded by Sichuan Province and Chengdu City.

 

About Shenzhen Share Investment

 

Founded in Shenzhen in 2007, Shenzhen Share Zeshan Precision Medicine Investment Partnership is the earliest limited partnership professional investment institution in China. So far, it has established 11 funds managing funds of more than RMB 8 billion and has invested more than 180 enterprises with its professional investment team of 50 people. The investment scope of Share Investment in medical and health industries covers new drug research and development, biotechnology, innovative devices, medical and health services and other subdivided fields, and it has formed a portfolio with new drug research and development and biotechnology as its prominent characteristics. Share Investment, with its role in VC and capital sector as the link, to build an effective communication bridge between industry, academia and entrepreneurs, so as to achieve resource integration and complementary advantages, create a good project "Encounter System" and bring rich and high-quality project sources for the funds operated by it.

 

About Changjiang Securities Innovation Investment

 

Changjiang Securities was founded in 1991, and its predecessor is Hubei Securities. Through the development for more than 20 years in Hubei, it has grown into a comprehensive financial service company with strong strength, complete functions, standard management and prominent performance. Founded in 2016, Changjiang Securities Innovation Investment (Hubei) Co., Ltd. is a wholly-owned subsidiary of Changjiang Securities, with the registered capital of RMB 2 billion. It is the only investment platform of Changjiang Securities Group that is engaged in equity investment with its own funds. Its investment directions focus on three industries: consumer electronics, new energy, and biopharm. Since its set up 4 years ago, it has completed the investment in over ten projects, among which 2 have been successfully listed and 3 are under examination.

 

About Shining Capital

 

Founded in 2016, Shining Capital is headquartered in Beijing Economic-Technological Development Area, focusing on venture capital in the medical health and life sciences. Now it is a vice president unit of Biomedical Professional Committee of Beijing Venture Capital Innovation Service Alliance, and also a member unit of Asset Management Association of China. The fund management team of Shining Capital has profound medical and health industry background and rich experience in venture capital. Since it was registered as a private fund manager, Shining Capital has managed three funds: “Phase I of Beijing Yizhuang Biomedical Investment Fund (scale: RMB 800 million)”, “Phase II of Beijing Yizhuang Biomedical Investment Fund (scale: RMB 1 million)” and “Beijing Yizhuang Investment Fund for Small and Medium-sized Biomedical Enterprises (scale RMB 270 million)”. The management scale exceeds RMB 2 billion, and the investment stages cover Angle, VC and PE. It has completed the investment in over 20 medical and health projects.

 

 

Baili Pharm has been awarded the best industrial enterprise in China's pharmaceutical R&D product line for the seventh consecutive year on the 2021 Annual Conference for China Pharmaceutical Industry Information.

 

 

The year 2021 is also a critical year for Baili Pharm to develop original new drugs and generic drugs rapidly.

 

Original new drugs

Baili Pharm has been focusing on the breakthrough effect of tumor treatment, and now it has built various "break-through" product lines. The world's leading 2 double-antibody projects and the world's leading 3 tetra-specific antibodies have showed good safety, tolerability, and pharmacokinetic characteristics in clinical study and obtained positive efficacy signals. The world's leading “double-antibody ADC” project has been applied for IND.

 

Generic drugs

Multiple series of new drugs for children are about to be approved for marketing. Baili Pharm, as one of member units of China Children's Medicine R&D and Industrialization Alliance”, is expecting to make contributions to the medicines for children in emergency shortage.

 

 

An excellent park will incubate excellent enterprises, and excellent enterprises will produce excellent results.

 

The Park will continue to assist enterprises to achieve growth and breakthroughs.

 

 

Source: Official Weibo of Chengdu Xiling Lab and Baili Pharm